Influence of lifestyle-related diseases and age on the development and progression of non-alcoholic fatty liver disease

Hepatology Research

Volumn 45, Issue 5, 2015, Pages 548-559

  Shima, Toshihide ^a   Seki, Kojiro ^a   Umemura, Atsushi ^a   Ogawa, Rie ^a   Horimoto, Ryuji ^a   Oya, Hirohisa ^a   Sendo, Rei ^a   Mizuno, Masayuki ^a   Okanoue, Takeshi ^a  

^a Saiseikai Imperial Gift Foundation Inc Saiseikai Suita Hospital   (Japan)

Author keywords

Aging; Lifestyle related disease; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; CHOLESTEROL; COLLAGEN TYPE 7; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; HYALURONIC ACID; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DISEASE COURSE; DYSLIPIDEMIA; FEMALE; FERRITIN BLOOD LEVEL; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERTENSION; LIFESTYLE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; OBESITY; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; THROMBOCYTE COUNT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84928203439     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12384     Document Type: Article

References (32)

1. Annual change in frequency of abnormal value in lifestyle-related diseases. Available at: http://www.ningen-dock.jp/wp/common/data/other/release/dock-genkyou_h24.pdf. Accessed April 6, 2014.
2. Ikai I, Kudo M, Arii S etal. Report of the 18th follow-up survey of primary liver cancer in Japan. Hepatol Res 2010; 40: 1043-1059.
3. Umemura T, Ichijo T, Yoshizawa K etal. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol 2009; 44: 102-107.
4. El-serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126: 460-468.
5. Welzel TM, Graubard BI, Zeuzem S etal. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-medicare database. Hepatology 2011; 54: 463-471.
6. Kasuga M, Ueki K, Tajima N etal. Report of the Japan Diabetes Society/Japanese Cancer Association joint committee on diabetes and cancer. Cancer Sci 2013; 104: 965-976.
7. Tobias DK, Pan A, Jackson CL etal. Body-mass index and mortality among adults with incident type 2 diabetes. N Engl J Med 2014; 370: 233-244.
8. Fallo F, Dalla Pozza A etal. Nonalcoholic fatty liver disease, adiponectin and insulin resistance in dipper and nondipper essential hypertensive patients. J Hypertens 2008; 26: 2191-2197.
9. Okanoue T, Yasui K, Itoh T. Non-alcoholic fatty liver disease in Japan. In: Farrell GC, McCullough AJ, Day CP, eds. Non-Alcoholic Fatty Liver Disease. A Practical Guide. Oxford: Wiley-Blackwell, 2013; 217-227.
10. Matteoni CA, Younossi ZM, Gramlich T etal. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419.
11. Adams LA, Lymp JF, St Sauver J etal. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-121.
12. Chalasani N, Younossi Z, Lavine JE etal. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-2023.
13. Sumida Y, Yoneda M, Hyogo H etal. A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol 2011; 46: 257-268.
14. Ochi H, Hirooka M, Koizumi Y etal. Real-time tissue elastography for evaluation of hepatic fibrosis and portal hypertension in nonalcoholic fatty liver diseases. Hepatology 2012; 56: 1271-1278.
15. Chen J, Talwalkar JA, Yin M etal. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology 2011; 259: 749-756.
16. Brunt EM, Janney CG, Di Bisceglie AM etal. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474.
17. Shiga T, Moriyoshi Y, Nagahara H etal. Nonalcoholic fatty liver is a risk factor for postprandial hyperglycemia, but not for impaired fasting glucose. J Gastroenterol 2009; 44: 757-764.
18. Kawamura Y, Arase Y, Ikeda K etal. Large-scale long-term follow-up study of Japanese patients with non-alcoholic fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol 2012; 107: 253-261.
19. Hotta N, Nakamura J, Iwamoto Y etal. Causes of death in Japanese diabetics based on the results of a survey of 18, 385 diabetics during 1991-2000-Report of committee on cause of death in diabetes mellitus. J Jpn Diabetes Soc 2007; 50: 47-61.
20. Shima T, Uto H, Ueki K etal. Clinicopathological features of liver injury in patients with type 2 diabetes mellitus and comparative study of histologically proven nonalcoholic fatty liver diseases with or without type 2 diabetes mellitus. J Gastroenterol 2013; 48: 515-525.
21. Neuschwander-Tetri BA, Clark JM, Bass NM etal. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010; 52: 913-924.
22. Loomba R, Abraham M, Nonalcoholic Steatohepatitis Clinical Research Network etal. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 2012; 56: 943-951.
23. Miyaaki H, Ichikawa T, Nakao K etal. Clinicopathological study of nonalcoholic fatty liver disease in Japan: the risk factors for fibrosis. Liver Int 2008; 28: 519-524.
24. Speliotes EK, Massaro JM, Hoffmann U etal. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology 2010; 51: 1979-1987.
25. Harrison SA, Oliver D, Arnold HL etal. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008; 57: 1441-1447.
26. Angulo P, Hui JM, Marchesini G etal. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-854.
27. Fontana L, Zhao E, Amir M etal. Aging promotes the development of diet-induced murine steatohepatitis but not steatosis. Hepatology 2013; 57: 995-1004.
28. Kawaguchi T, Sumida Y, Umemura A etal. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS ONE 2012; 7: e38322.
29. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010; 52: 1836-1846.
30. Eguchi Y, Hyogo H, Ono M etal. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol 2012; 47: 586-595.
31. Kamada Y, Kiso S, Yoshida Y etal. Estrogen deficiency worsens steatohepatitis in mice fed high-fat and high-cholesterol diet. Am J Physiol Gastrointest Liver Physiol 2011; 301: G1031-1043.
32. Yang JD, Abdelmalek MF, Pang H etal. Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology 2014; 59: 1406-1414.